The U.S. apoptosis assay market is projected to reach $6.18 billion and Europe $4.37 billion by 2035, supported by pharmaceutical R&D, precision medicine, cancer research, and advanced flow cytometry and imaging technologies.
The U.S. apoptosis assay market is projected to reach $6.18 billion and Europe $4.37 billion by 2035, supported by pharmaceutical R&D, precision medicine, cancer research, and advanced flow cytometry and imaging technologies.